Letter to the editor: Neutralizing antibodies for the treatment of COVID-19
Acta Pharm Sin B
.
2021 Jan;11(1):304-307.
doi: 10.1016/j.apsb.2020.10.025.
Epub 2020 Nov 16.
Authors
Zeqi Zhou
1
,
Xiangbin Wang
2
,
Yankai Fu
1
,
Xiqing Zhang
1
,
Changxiao Liu
3
Affiliations
1
Dynamiker Biotechnology Sub-Center, Beijing Key Laboratory for Mechanism Study and Precision Diagnosis of Invasive Fungal Diseases, Tianjin 300467, China.
2
Beijing Antai Zhiyuan Technology Co., Ltd., Beijing 102206, China.
3
State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin 300462, China.
PMID:
33224722
PMCID:
PMC7668178
DOI:
10.1016/j.apsb.2020.10.025
No abstract available
Keywords:
COVID-19; Neutralizing antibody therapy; SARS-CoV-2.